Aminosteroidal neuromuscular blocking agent

"Aminosteroidal neuromuscular blocking agents" are not a specific single molecule or receptor, but rather a chemical class of nondepolarizing neuromuscular blocking agents (NMBAs) structurally related to steroids. They include drugs such as rocuronium, vecuronium, pancuronium, and pipecuronium. These agents act by competitively antagonizing the nicotinic acetylcholine receptor at the neuromuscular junction, thereby inhibiting acetylcholine-mediated neuromuscular transmission and producing skeletal muscle relaxation during surgical procedures or mechanical ventilation. This class differs from benzylisoquinolinium NMBA agents in metabolic pathways and side effect profiles, notably with minimal histamine release and predominant hepatic and/or renal elimination[3][5][7]. **Clarification**: The name refers to a chemical class, not a specific target molecule, receptor, or protein; the true pharmacological target is the muscle-type nicotinic acetylcholine receptor (nAChR), not the "aminosteroidal NMBA" itself[3][7]. To extract structured information about a therapeutic target, the correct entry should be "Nicotinic acetylcholine receptor (muscle type)" or "Neuromuscular acetylcholine receptor.

Other names

Aminosteroid nondepolarizing neuromuscular blockerAminosteroidal NMBA

Competitive antagonism of nicotinic acetylcholine receptor at the neuromuscular junction